As a point of reference, Rachel McMinn's September 2012 piece had implied US sales of $68 for Sprycel - $33 for Tasigna and (her average of the two) estimate of $52 for Iclusig.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.